Jennifer Blackmore

Jennifer graduated with a B.Sc. (hons.) in Biochemistry from the University of Warwick in 2022. Her 4-year degree included a Placement Year during which she worked as a laboratory assistant in industry, fulfilling a number of roles related to research and diagnostic testing. Jennifer completed her undergraduate research dissertation in the field of neuroscience, carrying out detailed anatomical studies that were designed to elucidate seizure-related phenotypic changes in brain microglia in mouse models of epilepsy.

Jennifer joined the Magill Group in February 2023. Her work is centred on providing research support for the development and delivery of novel in vivo platforms for drug discovery in Parkinson’s disease, as part of the Unit’s translational research venture with partners at the University of Oxford and in industry.